Zoetis

PharmaceuticalsParsippany, New JerseyZTSAbout 14,500 employees

More about Zoetis

Animal health company that makes medicines, vaccines and diagnostics for pets and livestock

Revenue

$9.5B

Fiscal 2025, up 2.3%

Employees

About 14,500

As of December 2025

Stock

ZTS

New York Stock Exchange

Headquarters

Parsippany, New Jersey

CEO

Kristin Peck

Since January 2020

BrandsSimparica Trio, Apoquel, Cytopoint, Librela, Revolution

Current strategyAdjusting its commercial strategy against new competition, with targeted investment, faster innovation and business development

Recent workforce changes$75M of mainly employee termination costs in Q2 2026 under a cost and productivity program; role count not disclosed

CompetitorsElanco, Merck Animal Health, Boehringer Ingelheim

Checked October 11, 2026 · Sources: sec.gov, sec.gov (2)

No source-backed updates for Zoetis yet. They appear here when a public report or filing covers the company.

No one has posted about Zoetis yet. Be the first to post ›

Follow Zoetis in a feed reader, no account needed: RSS feed